AgingResearch.NewsJoin free

Prednisolone

InterventionApproved 1955

7 papers study it12 more mention it5 findings

PubChemChEBIMeSH

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

About aging: trials about aging, of every trial that tests the drug for any use.

No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.

  • 2 independent labs in 1 country
  • 370 trials, none about aging, 138 with no results posted
  • Funder: Royal Adelaide Hospital
  • Humans6
  • Animals1

Outcomes

4

LTB4R

upin human cells2

2 studies

  1. Prednisolone increases LTB4R in human cells.

    “Treatment with 1 μM prednisolone in vitro resulted in upregulation of BLTR1 expression in pro-inflammatory CD28nullCD8+ cells”

    CellsCD28nullCD8+ cells1 μM

    BLTR1 Is Decreased in Steroid Resistant Pro-Inflammatory CD28nullCD8+ T Lymphocytes in Patients with COPD-The Spillover Hypothesis Explained?

    BiologySep 20, 2023

  2. Prednisolone increases LTB4R in human cells.

    “Treatment with 1μM prednisolone in vitro resulted in upregulation of BLTR1 expression in pro-inflammatory CD28nullCD8+ cells”

    Cellsin vitro1 μM

    BLTR1 is decreased in steroid resistant pro-inflammatory CD28nullCD8+ T lymphocytes in patients with COPD - the spillover hypothesis explained?

    Research SquareDec 2, 2022Preprint

More on LTB4R

Chemotaxis

upin human cells1

1 study

  1. Prednisolone increases chemotaxis in human cells.

    “Treatment with 1 μM prednisolone in vitro resulted in upregulation of BLTR1 expression in pro-inflammatory CD28nullCD8+ cells and migration to LB4.”

    Cellsin pro-inflammatory CD28nullCD8+ cells1 μM

    BLTR1 Is Decreased in Steroid Resistant Pro-Inflammatory CD28nullCD8+ T Lymphocytes in Patients with COPD-The Spillover Hypothesis Explained?

    BiologySep 20, 2023

Ultimate strain

downin rats1

1 study

  1. Prednisolone decreases ultimate strain in rats.

    “Prednisolone increased tensile strength and induced some decrease of ultimate strain and time until break.”

    Animalsskin10 days

    Strain of rat skin at constant load (creep experiments): influence of age and desmotropic agents

    GerontologyJan 1, 1977

Tensile strength

upin rats1

1 study

  1. Prednisolone increases tensile strength in rats.

    “Prednisolone increased tensile strength and induced some decrease of ultimate strain and time until break.”

    Animalsskin10 days

    Strain of rat skin at constant load (creep experiments): influence of age and desmotropic agents

    GerontologyJan 1, 1977

Trials

0 about aging, of 370

Approved

  • FDA Meticortelone

    May 22, 1955Discontinued

  • FDA Delta-Cortef

    Jun 21, 1955Discontinued

  • FDA Sterane

    Jul 1, 1955Discontinued

  • FDA Meti-Derm

    Feb 24, 1956Discontinued

  • FDA Pred Mild

    Nov 10, 1972PRED MILD ® is indicated for the treatment of mild to moderate noninfectious allergic and inflammatory disorders of the lid, conjunctiva,…

  • FDA Pred Forte

    May 30, 1973Prednisolone acetate ophthalmic suspension 1% is indicated for the treatment of steroid-responsive inflammation of the palpebral and…

All 14

  • FDA Econopred

    Jul 10, 1973Discontinued

  • FDA Omnipred

    Jul 10, 1973injury, burns, inflammatory conditions

  • FDA Pediapred

    May 28, 1986Adrenal Hyperplasia, Congenital, Anemia, Hemolytic, Asthma, Colitis, Ulcerative, Dermatitis, Dermatitis, Atopic, Dermatitis, Contact, Hypersensitivity, Nephrotic Syndrome, Pemphigus, Rhinitis, Allergic, Thrombocytopenia, Thyroiditis, Cancer, Idiopathic Nephrotic Syndrome, proteinuria, lupus erythematosus, Hypercalcemia, uremia, mycosis

  • FDA Sterane

    May 12, 1998Discontinued

  • FDA Orapred ODT

    Jun 1, 2006Adrenal Hyperplasia, Congenital, Anemia, Hemolytic, Colitis, Ulcerative, Dermatitis, Dermatitis, Atopic, Dermatitis, Contact, Hypersensitivity, Pemphigus, Rhinitis, Allergic, Thyroiditis, Crohn's Disease, Hypercalcemia of Malignancy, organ transplantation, mycosis

  • FDA FLO-Pred

    Jan 17, 2008Discontinued

  • FDA Hydeltrasol

    Discontinued

  • FDA Hydeltrasol

    Discontinued

Repurposing

40 of 131

In trials

  • Precursor cell lymphoblastic leukemia lymphoma

    Phase 4Completed30 trials

  • Prostatic Neoplasms

    Phase 4Results posted19 trials

  • Hodgkin Disease

    Phase 4Completed10 trials

  • Burkitt lymphoma

    Phase 4Completed8 trials

  • IGA Glomerulonephritis

    Phase 4Recruiting5 trials

  • Lymphoma, Large-Cell, Anaplastic

    Phase 4Completed4 trials

40 of 47

  • Purpura, Thrombocytopenic, Idiopathic

    Phase 4Status unknown4 trials

  • Bell Palsy

    Phase 4Completed3 trials

  • Lipoid Nephrosis

    Phase 4Completed3 trials

  • Bronchiolitis Obliterans Syndrome

    Phase 4Completed2 trials

  • Chronic renal insufficiency

    Phase 4Recruiting2 trials

  • Habitual Abortion

    Phase 4Recruiting2 trials

  • Immunoglobulin G4-Related Disease

    Phase 4Completed2 trials

  • Residual Neoplasm

    Phase 4Completed2 trials

  • Respiratory Sounds

    Phase 4Status unknown2 trials

  • Acute Gout

    Phase 4Terminated1 trial

  • Immune reconstitution inflammatory syndrome

    Phase 4Terminated1 trial

  • Kidney transplant

    Phase 4Completed1 trial

  • Mikulicz's disease

    Phase 4Completed1 trial

  • Progressive multifocal leukoencephalopathy

    Phase 4Terminated1 trial

  • Virus disease

    Phase 4Status unknown1 trial

  • Lymphoma, large b-cell, diffuse

    Phase 3Results posted21 trials

  • Leukemia, Biphenotypic, Acute

    Phase 3Active, not recruiting6 trials

  • Alcoholic hepatitis

    Phase 3Recruiting3 trials

  • Interdigitating Dendritic Cell Sarcoma

    Phase 3Recruiting3 trials

  • Lymphoma, B-Cell, Marginal Zone

    Phase 3Completed3 trials

  • Lymphoma, Large-Cell, Immunoblastic

    Phase 3Completed3 trials

  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

    Phase 3Active, not recruiting3 trials

  • Allergic Bronchopulmonary Aspergillosis

    Phase 3Recruiting2 trials

  • Hepatic insufficiency

    Phase 3Recruiting2 trials

  • Infantile Spasms

    Phase 3Completed2 trials

  • Leukemia, Lymphocytic, Chronic, B-Cell

    Phase 3Completed2 trials

  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

    Phase 3Active, not recruiting2 trials

  • Active Rheumatoid Arthritis

    Phase 3Results posted1 trial

  • Intermediate uveitis

    Phase 3Completed1 trial

  • Mature b cell non hodgkin lymphoma

    Phase 3Active, not recruiting1 trial

  • Renal transplantation

    Phase 3Completed1 trial

  • Endometrial neoplasm

    Phase 2Recruiting2 trials

  • Hypertrophic Pyloric Stenosis

    Phase 2Status unknown2 trials

  • B-cell leukemia

    Phase 2Active, not recruiting1 trial

Readouts due

Stopped

  • NCT02613910TerminatedPemphigus

    Novartis has acquired the rights to ofatumumab and terminated the OPV116910 and OPV117059 studies. This decision is not linked to any safety consideration.

  • NCT00984568TerminatedUlcerative colitis

    Due to slow recruitment the study was stopped prematurely.

  • NCT01939691TerminatedMacular edema

    Difficulty enrolling

  • NCT02949232TerminatedPsychotic disorders

    Difficulties with recruitment

  • NCT05698680TerminatedAcute Gout

    The study was terminated due to an inability to reach the planned sample size, despite efforts to enhance recruitment.

  • NCT01211665TerminatedImmune reconstitution inflammatory syndrome

    This study was stopped prematurely due to lack of enrollment within a 1-5-year period.

All 11

  • NCT00456339TerminatedObstructive sleep apnea

    Problems recruiting; patient relapse following treatment

  • NCT03368664TerminatedMultiple sclerosis

    Enrolment formally closed earlier than planned due to recruitment challenges.

  • NCT05570409TerminatedMyocarditis

    Premature end of recruitment due to lack of eligible patients. Within two years of recruitment only nine patients could be randomized out of 130 required patients as per trial protocol.

  • NCT02935101TerminatedOpioid-related disorders

    difficulties in recruiting study participants

  • NCT00521989TerminatedOsteoarthritis

    CRx-102-006 study results, negative

Trial sponsors

Latest

Nov 2025: 0Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 1May 2026: 1Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 1Oct 2026: 03 papers in 12 months

Related